5:54 PM
Sep 10, 2013
 |  BC Extra  |  Clinical News

ChemoCentryx slides on diabetic nephropathy data

ChemoCentryx Inc. (NASDAQ:CCXI) fell $2.01 (24%) to $6.25 on Tuesday after reporting interim data from 332 evaluable patients in a Phase II trial evaluating CCX140 to treat diabetic nephropathy. In the trial, once-daily oral CCX140 plus standard of...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >